Development of porous silicon nanocarriers for parenteral peptide delivery.

Porous silicon (PSi) is receiving growing attention in biomedical research, for example, in drug and peptide delivery. Inspired by several advantages of PSi, herein, thermally oxidized (TOPSi, hydrophilic), undecylenic acid-treated thermally hydrocarbonized (UnTHCPSi, moderately hydrophilic), and thermally hydrocarbonized (THCPSi, hydrophobic) PSi nanocarriers are investigated for sustained subcutaneous (sc) and intravenous (iv) peptide delivery. The route of administration is shown to affect drastically peptide YY3-36 (PYY3-36) release from the PSi nanocarriers in mice. Subcutaneous nanocarriers are demonstrated to be capable to sustain PYY3-36 delivery over 4 days, with the high absolute bioavailability values of PYY3-36. The pharmacokinetic parameters of PYY3-36 are presented to be similar between the sc PSi nanocarriers despite surface chemistry. In contrast, iv-delivered PSi nanocarriers display significant differences between the surface types. Overall, these results demonstrate the feasibility of PSi nanocarriers for the sustained sc delivery of peptides.

[1]  A. Jalanko,et al.  Native and Complexed IGF-1: Biodistribution and Pharmacokinetics in Infantile Neuronal Ceroid Lipofuscinosis , 2012, Journal of drug delivery.

[2]  Mesoporous Silicon (PSi) for Sustained Peptide Delivery: Effect of PSi Microparticle Surface Chemistry on Peptide YY3-36 Release , 2012, Pharmaceutical Research.

[3]  C. Prestidge,et al.  Surface chemical modification to control molecular interactions with porous silicon. , 2011, Journal of colloid and interface science.

[4]  A. Seifalian,et al.  Current trends in the application of nanoparticles in drug delivery. , 2011, Current medicinal chemistry.

[5]  K. Järvinen,et al.  Nanostructured porous silicon microparticles enable sustained peptide (Melanotan II) delivery. , 2011, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[6]  M. Ferrari,et al.  In vivo evaluation of safety of nanoporous silicon carriers following single and multiple dose intravenous administrations in mice. , 2010, International journal of pharmaceutics.

[7]  Vesa-Pekka Lehto,et al.  Biocompatibility of thermally hydrocarbonized porous silicon nanoparticles and their biodistribution in rats. , 2010, ACS nano.

[8]  M Ferrari,et al.  Size and shape effects in the biodistribution of intravascularly injected particles. , 2010, Journal of controlled release : official journal of the Controlled Release Society.

[9]  M. Khrestchatisky,et al.  Synthetic therapeutic peptides: science and market. , 2010, Drug discovery today.

[10]  Vesa-Pekka Lehto,et al.  In vivo delivery of a peptide, ghrelin antagonist, with mesoporous silicon microparticles. , 2009, Journal of controlled release : official journal of the Controlled Release Society.

[11]  R. Batterham,et al.  The role of peptide YY in appetite regulation and obesity , 2009, The Journal of physiology.

[12]  C. Beglinger,et al.  Pharmacokinetics and Pharmacodynamic Effects of Oral GLP‐1 and PYY3‐36: A Proof‐of‐concept Study in Healthy Subjects , 2008, Clinical pharmacology and therapeutics.

[13]  L. Karhunen,et al.  Effect of protein, fat, carbohydrate and fibre on gastrointestinal peptide release in humans , 2008, Regulatory Peptides.

[14]  Eric Pridgen,et al.  Factors Affecting the Clearance and Biodistribution of Polymeric Nanoparticles , 2008, Molecular pharmaceutics.

[15]  Mauro Ferrari,et al.  Mesoporous silicon particles as a multistage delivery system for imaging and therapeutic applications. , 2008, Nature nanotechnology.

[16]  J. Salonen,et al.  Surface chemistry and pore size affect carrier properties of mesoporous silicon microparticles. , 2007, International journal of pharmaceutics.

[17]  A. Astrup,et al.  Effect of subcutaneous injections of PYY1-36 and PYY3-36 on appetite, ad libitum energy intake, and plasma free fatty acid concentration in obese males. , 2007, American journal of physiology. Endocrinology and metabolism.

[18]  S. Heymsfield,et al.  Efficacy and safety of intranasal peptide YY3-36 for weight reduction in obese adults. , 2007, The Journal of clinical endocrinology and metabolism.

[19]  R. Pandey,et al.  Subcutaneous nanoparticle-based antitubercular chemotherapy in an experimental model. , 2004, The Journal of antimicrobial chemotherapy.

[20]  Rabah Boukherroub,et al.  Thermal Hydrosilylation of Undecylenic Acid with Porous Silicon , 2002 .

[21]  V. Mutt,et al.  Isolation of two novel candidate hormones using a chemical method for finding naturally occurring polypeptides , 1980, Nature.